Since the new year began, Rainbow Coral Corp. (OTCBB: RBCC) has wasted
no time in searching for new targets to add to its portfolio of projects
for commercialization. Last week, the Company’s executive leadership
accepted an invitation to tour a genome-mapping facility in Houston with
which RBCC could soon partner.
New healthcare innovations related to the human genome represent a
target-rich area of interest for RBCC. The Texas company currently being
reviewed performs tests to identify genetic markers in patients that can
potentially boost or nullify the effects of certain medications.
Such testing could dramatically change the way medications are
prescribed, potentially fostering a significant reduction in global
health care costs.
“Knowing specifics about an individual’s genetic make-up can greatly
assist a patient’s doctor in determining correct doses of medications as
well as ruling out medications that could prove harmful,” said RBCC CEO
Patrick Brown. “Genome mapping opens up a host of new possibilities for
doctors and patients alike, and we’re very interested in the
technology’s economic potential.”
As the company searches for its next partner, RBCC’s biotech subsidiary
Rainbow Biosciences remains close to a joint venture deal with Amarantus
Bioscience, makers of exciting new diagnostic tools and therapies for
neurological diseases such as Parkinson’s.
Amarantus recently announced highly promising results in new animal
trials of its forthcoming Parkinson’s therapeutic, known as MANF.
Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott
Laboratories (NYSE: ABT).
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC).
The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit our website at www.rainbowbiosciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.